Chawla Lakhmir S 4
4 · REVELATION BIOSCIENCES, INC. · Filed Feb 5, 2026
Research Summary
AI-generated summary of this filing
REVELATION BIOSCIENCES (REVB) Director Lakhmir Chawla Sells 2,261 Shares
What Happened Lakhmir S. Chawla, a director of Revelation Biosciences, reported a disposition of 2,261 shares on 2026-02-03 to satisfy tax withholding obligations tied to the vesting of restricted stock awards. The shares were disposed at a weighted average price of $1.85 per share for proceeds of approximately $4,183. The transaction is coded as F (payment of exercise price or tax liability) and was mandatory to cover taxes.
Key Details
- Transaction date: 2026-02-03; Form 4 filed 2026-02-05 (no late filing indicated in this report).
- Shares sold/disposed: 2,261 (post 1-for-4 reverse split; see note below).
- Price: weighted average $1.85; sales occurred in multiple trades at prices ranging $1.84–$1.87.
- Purpose: Issuer sold shares on behalf of the reporting person solely to satisfy required tax obligations upon RSU vesting; sale was mandatory and not at the reporting person’s discretion.
- Shares owned after the transaction: not specified in the provided filing data.
Context This was a routine tax-withholding sale (code F) following RSU vesting, not an open-market discretionary sale. Such mandatory withholdings are common and generally do not signal the insider’s view on the company’s prospects. The footnotes note that all share counts reflect a 1-for-4 reverse split effective January 28, 2026.
Insider Transaction Report
- Tax Payment
Common Stock
[F1][F2][F3]2026-02-03$1.85/sh−2,261$4,183→ 12,158 total
Footnotes (3)
- [F1]All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.
- [F2]Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.